Sage Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	540.78	453.86	486.73	475.95	403.97
Revenue Growth (YoY)	13.62%	-6.75%	2.27%	17.82%	-
Gross Profit	529.42	453.86	486.73	475.95	403.97
Selling, General & Admin	151.04	136.81	115.63	212.98	214.6
Other Operating Expenses	71.04	63.26	143.61	105.71	104.44
Operating Expenses	301.55	265.75	328.21	422.46	440.39
Operating Income	227.86	188.11	158.52	53.48	-36.42
Interest Expense	-87.36	-91.03	-121.23	-107.23	-83.07
Interest & Investment Income	25.44	22.65	2.07	1.17	2.24
Earnings From Equity Investments	-0.99	-0.57	-0.54	0.07	0.01
Currency Exchange Gain (Loss)	9.51	26.84	-17.45	-114.06	-21.03
Other Non Operating Income (Expenses)	-3.04	-5.66	0.14	-0.02	-15.16
EBT Excluding Unusual Items	171.42	140.34	21.51	-166.59	-153.42
Gain (Loss) on Sale of Assets	7.63	6.79	7.53	15.48	-1.68
Asset Writedown	43.02	46.78	18.72	65.22	-7.5
Pretax Income	222.07	193.92	47.76	-85.88	-162.6
Income Tax Expense	-39.61	-36.24	5.63	3.27	13.37
Earnings From Continuing Operations	261.67	230.16	42.13	-89.15	-175.97
Earnings From Discontinued Operations	-	-	18.9	-	-
Net Income to Company	261.67	230.16	61.03	-89.15	-175.97
Minority Interest in Earnings	0.37	0.33	-	1.02	0.28
Net Income	262.04	230.49	61.03	-88.13	-175.69
Net Income to Common	262.04	230.49	61.03	-88.13	-175.69
Net Income Growth	-	277.67%	-	-	-
Shares Outstanding (Basic)	466	424	127	127	-
Shares Outstanding (Diluted)	466	424	127	127	-
Shares Change (YoY)	266.88%	233.85%	-	-	-
EPS (Basic)	0.56	0.54	0.48	-0.69	-
EPS (Diluted)	0.56	0.54	0.48	-0.69	-
EPS Growth	-	13.12%	-	-	-
Free Cash Flow	218.59	215.66	185.19	62.02	42.91
Free Cash Flow Per Share	0.47	0.51	1.46	0.49	-
Gross Margin	97.90%	100.00%	100.00%	100.00%	100.00%
Operating Margin	42.14%	41.45%	32.57%	11.24%	-9.01%
Profit Margin	48.46%	50.78%	12.54%	-18.52%	-43.49%
Free Cash Flow Margin	40.42%	47.52%	38.05%	13.03%	10.62%
EBITDA	309.09	249.67	227.48	155.93	83.45
EBITDA Margin	57.16%	55.01%	46.74%	32.76%	20.66%
D&A For EBITDA	81.22	61.56	68.97	102.45	119.86
EBIT	227.86	188.11	158.52	53.48	-36.42
EBIT Margin	42.14%	41.45%	32.57%	11.24%	-9.01%
Effective Tax Rate	-	-	11.79%	-	-
Revenue as Reported	625.59	529.37	502.57	504.69	446.15

Source: S&P Global Market Intelligence. Standard template. Financial Sources.